Table 2.
Summary of HRs and their 95% CI
| Study | Year | Country | Tumor type | Outcome | HR | 95% CI | NOS |
|---|---|---|---|---|---|---|---|
| Hu et al. [21] | 2011 | America | EC |
OS DFS |
1.41 1.39 |
0.81–2.44 0.82–2.35 |
8 |
| Lin et al. [29] | 2015 | China | EC | OS | 3.182 | 1.273–10.184 | 6 |
| Osawa et al. [24] | 2011 | Japan | GC | OS | 0.2 | 0.06–0.68 | 6 |
| Hui et al. [22] | 2015 | China | GC | OS | 2.327 | 1.099–4.927 | 7 |
| Wei et al. [30] | 2015 | China | GC | OS | 2.31 | 0.13–40.12 | 8 |
| Zhang et al. [31] | 2015 | China | GC | OS | 1.33 | 1.14–1.61 | 8 |
| Yang et al. [23] | 2015 | China | GC | OS | 3.05 | 0.6–15.50 | 8 |
| Li et al. [32] | 2015 | China | HCC |
OS PFS |
1.81 1.22 |
1.03–3.18 0.92–1.62 |
6 |
| Yang et al. [33] | 2013 | China | HCC | OS | 3.54 | 1.67–7.52 | 7 |
| Cui et al. [34] | 2015 | China | HCC |
OS RFS |
1.44 1.49 |
1.13–1.72 1.15–1.79 |
8 |
| Xu et al. [20] | 2015 | China | HCC |
OS RFS |
1.96 1.96 |
1.04–3.57 1.10–3.45 |
8 |
| Ohuchida et al. [35] | 2011 | Japan | PC | OS | 2.92 | 1.303–6.295 | 8 |
| Jamieson et al. [36] | 2012 | Scotland | PC | OS | 6.67 | 2.684–16.573 | 8 |
| Long et al. [10] | 2016 | China | PC | OS | 1.88 | 1.35–2.64 | 8 |
| Sun et al. [37] | 2018 | China | PC | OS | 2.24 | 1.38–3.36 | 7 |
| Zhang et al. [25] | 2017 | China | CRC | OS | 1.76 | 1.01–3.05 | 6 |
| Hasakova et al. [38] | 2019 | Slovakia | CRC | OS | 1.34 | 0.65–2.75 | 8 |
| Gao et al. [39] | 2014 | China | CRC |
DFS DFS |
3.819 2.973 |
2.438–5.983 1.339–6.602 |
8 |
| Jin et al. [11] | 2013 | China | GBC | OS | 2.37 | 1.11–5.06 | 8 |
Abbreviations: 95%CI 95% confidence interval, CRC colorectal cancer, DFS disease-free survival, EC esophageal cancer, GBC gallbladder cancer, GC gastric cancer, HCC hepatocellular carcinoma, HR hazard ratio, OS overall survival, PC pancreatic cancer, PFS progressive-free survival, RFS recurrence-free survival